EUCTR2006-000880-27-ES进行中（未招募）不适用
A phase II study of oral LBH589 in adult patients with refractory cutaneous T-Cell lymphoma
ovartis Farmacéutica, S.A.0 个研究点目标入组 139 人开始时间: 2012年4月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 139
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent obtained prior to any screening procedures
- •2. Age ? 18 years old
- •3. Patients with biopsy-confirmed stages IB-IVA mycosis fungoides or Sézary syndrome. Patients with SS who have bone marrow involvement are also eligible. Patients with transformed CTCL are eligible. Disease stage for eligibility is based on the stage at time of study enrollment. NOTE: patients with any history of visceral involvement due to CTCL (i.e. stage IVB disease) are not eligible for this study.
- •4. Patients must have received at least two prior systemic therapy regimens. Systemic regimens include oral bexarotene, PUVA, photophoresis, chemotherapy such as methotrexate, and interferon. Topical steroids alone are not considered as a treatment regimen.
- •5. Patients must have had disease progression on or following their most recent treatment regimen. Patients are also eligible if they had an inadequate response to their most recent treatment regimen defined as stable disease as the best response after at least 3 months of therapy.
- •6. Patients will be accrued to one of two groups:
- •Group 1: Patients previously treated with oral bexarotene. This group includes patients who had:
- •? Disease progression on following treatment oral bexarotene, OR
- •? An inadequate response to oral bexarotene treatment defined as stable disease as the best response after at least 3 months of treatment, OR
- •? Intolerance of oral bexarotene defined as patients who discontinued oral bexarotene treatment due to adverse events.
- •Group 2: Patients who have not had prior oral bexarotene treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 89
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Prior treatment with an HDAC inhibitor for CTCL.
- •2. Patients with visceral disease including CNS involvement (i.e. stage IVB CTCL). Note; Patients with SS who have bone marrow involvement are eligible.
- •3. Patients who have been previously treated with LBH589.
- •4. Impaired cardiac function
- •5. Concomitant use of drugs with a risk of causing torsades de pointes
- •6. Patients who have received chemotherapy or any investigational drug or undergone major surgery ?3 weeks prior to starting study drug or who have not recovered from side effects of such therapy
- •7. Less than 3 months since prior electron beam therapy
- •8. Women who are pregnant or breast feeding, or women of childbearing potential (WOCBP) not willing to use a double method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at baseline.
- •9. Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a condom.
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell LymphomaEUCTR2006-000880-27-ITOVARTIS FARMA118
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell LymphomaAdult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). All patients must have received at least two prior treatment regimens for their MF or SS, at least one of which was a systemic regimen.MedDRA version: 8.1Level: LLTClassification code 10011679Term: Cutaneous T-cell lymphoma refractoryEUCTR2006-000880-27-FIovartis Pharma Services AG132
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Multiple Myeloma Who Have Received At Least Two Prior Lines Of Therapy And Whose Disease Is Refractory To The Most Recent Line Of Therapy - NDMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomamultiple myelomaEUCTR2006-004087-31-ITOVARTIS FARMA144
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell LymphomaEUCTR2006-000880-27-HUovartis Pharma Services AG118
进行中（未招募）
不适用
A Phase II Study Of Oral LBH589 In Adult Patients With Refractory Cutaneous T-Cell LymphomaAdult patients with stages IB to IVA mycosis fungoides (MF) or Sézary syndrome (SS). All patients must have received at least two prior treatment regimens for their MF or SS, at least one of which was a systemic regimen.MedDRA version: 8.1Level: LLTClassification code 10011679Term: Cutaneous T-cell lymphoma refractoryEUCTR2006-000880-27-DEovartis Pharma Services AG132